CAJ | 학술논문

较多的研究显示,血清PSA值指导前列腺癌(prostate cancer,Pca)早期诊断的优势不足,例如PSA值在4～10 ng/mL.时,Pca穿刺阴性率占70%～80%.然而,阴性的穿刺结果并不能完全排除肿瘤的存在.寻找敏感性和特异性更高的肿瘤生物标志物一直是Pca研究的热点.目前,PSA衍生物、PCA3、TMPRSS2:ETS、GSTP1、AMACR、COLPH2、EPCA和肌氨酸以及多瘤标的联合应用研究受到广泛关注.本文中我们综述了这些分子标志物的研究近况,展望了多瘤标组合在Pca早期诊断中的价值和应用前景,为Pca的早期诊断和预后监测提供参考.
교다적연구현시,혈청PSA치지도전렬선암(prostate cancer,Pca)조기진단적우세불족,례여PSA치재4～10 ng/mL.시,Pca천자음성솔점70%～80%.연이,음성적천자결과병불능완전배제종류적존재.심조민감성화특이성경고적종류생물표지물일직시Pca연구적열점.목전,PSA연생물、PCA3、TMPRSS2:ETS、GSTP1、AMACR、COLPH2、EPCA화기안산이급다류표적연합응용연구수도엄범관주.본문중아문종술료저사분자표지물적연구근황,전망료다류표조합재Pca조기진단중적개치화응용전경,위Pca적조기진단화예후감측제공삼고.
More and more studies have revealed that the level of serum PSA has no ability to guide the early diagnosis of prostate cancer(Pca).For example, negative prostate biopsies are as high as 70%-80% for patients with serum prostate specific antigen(PSA)ranging between 4 ng/mL and 10 ng/mL. However, the negative results cannot exclude the existence of cancer. In the studies of the early diagnosis of Pca, investigators focused on seeking biomarkers that have higher sensitivity and specificity. Recently, PSA derivatives.HPCI,PCA3,TMPRSS2:ETS,GSTPl,AMACR,GOLPH2,EPCA, sarcosine, and the combination of multiple biomarkers are widely discussed. In this article, we have reviewed their recent development and the prospective value of the combination of multiple biomarkers, which may be helpful for the early diagnosis and the prognostic monitoring of patients with Pca.